Chugai And Taisho Pharmaceutical To Jointly Develop And Market Osteoporosis Drug
This article was originally published in PharmAsia News
Executive Summary
Chugai Pharmaceutical and Taisho Pharmaceutical signed an agreement May 14 to jointly develop and market activated vitamin D derivative ED-71 to treat osteoporosis. Originally developed by Chugai, ED-71 has higher bone strengthening effects compared to current activated vitamin D drugs, according to the companies. ED-71 is now in Phase III trials in Japan. (Click here for more - Japanese language)
You may also be interested in...
Fenty Cleanser Performance Claims Supported, But Influencer Videos Need Disclaimers – NAD
A National Advertising Division review of claims by LVMH-owned Fenty Skin determined makeup- and dirt-removal representations were substantiated by a study and subject questionnaire, but demo videos from paid endorsers must include disclosures about material connections in accordance with FTC guidelines.
Clinical Trial Diversity Requires Sponsors Work With An Assortment Of Patient Advocates, Community Organizations
US FDA oncology officials are concerned that the entities sponsors are consulting in developing and implementing clinical trial diversity plans are not sufficiently diverse themselves and do not represent patients in underserved communities.
Israeli Company Lands De Novo Clearance For Digital Bone Marrow Application
The US FDA has cleared a novel software application to enhance the analysis of bone marrow smears. Using the AI-powered tool, hematopathologists may be able to better diagnose various blood and marrow diseases.